OCUL Ocular Therapeutix Inc.

5.42
+0.18  (+3%)
Previous Close 5.24
Open 5.34
Price To Book -77.43
Market Cap 284,967,009
Shares 52,576,939
Volume 508,408
Short Ratio
Av. Daily Volume 1,089,788
Stock charts supplied by TradingView

NewsSee all news

  1. Ocular Therapeutix™ Reports Fourth Quarter and Year End 2019 Financial Results and Business Update

    Fourth Quarter DEXTENZA® Net Product Revenue of $1.6 million, a 433% Sequential Increase; Guiding First Quarter Total Net Product Revenue of $3.0 million to $3.2 million Presented Interim Clinical Data Releases for

  2. Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2019 Financial Results

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it

  3. Ocular Therapeutix™ Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40th Annual Health Care Conference

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced

  4. Ocular Therapeutix™ to Present at the Cowen and Company 40th Annual Health Care Conference

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

  5. Ocular Therapeutix™ Presents Data Demonstrating a Clinically-Meaningful Reduction in Intraocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Glaucoma 360 Conference

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, will today present data

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval June 21, 2019.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016. Additional Phase 3 trial initiation announced September 24, 2019. Top-line data due 2Q 2020.
DEXTENZA
Allergic conjunctivitis
Phase 3 data May 20, 2019 did not meet primary endpoint.
OTX-TP
Glaucoma and ocular hypertension
FDA approval announced December 3, 2018.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 1 initial data released April and May 2019.
OTX-TIC
Glaucoma and ocular hypertension
Phase 1 dosing of first patient announced February 20, 2019.
OTX-TKI
Wet Age-related Macular Degeneration (AMD)

Latest News

  1. Ocular Therapeutix™ Reports Fourth Quarter and Year End 2019 Financial Results and Business Update

    Fourth Quarter DEXTENZA® Net Product Revenue of $1.6 million, a 433% Sequential Increase; Guiding First Quarter Total Net Product Revenue of $3.0 million to $3.2 million Presented Interim Clinical Data Releases for

  2. Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2019 Financial Results

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it

  3. Ocular Therapeutix™ Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40th Annual Health Care Conference

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced

  4. Ocular Therapeutix™ to Present at the Cowen and Company 40th Annual Health Care Conference

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

  5. Ocular Therapeutix™ Presents Data Demonstrating a Clinically-Meaningful Reduction in Intraocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Glaucoma 360 Conference

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, will today present data

  6. Ocular Therapeutix™ to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

  7. Lyra Therapeutics Appoints Bradford Smith to its Board of Directors

    Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and

  8. Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

  9. Ocular Therapeutix™ Reports Third Quarter 2019 Financial Results and Business Update

    Over 7,000 Patients Treated Since Launch at more than 350 Surgical Sites Expanded the DEXTENZA® Field Team by 50% Implemented Restructuring Plan That Extends Cash Runway Through the Fourth Quarter of 2020 Topline

  10. Ocular Therapeutix Announces Strategic Update and Operational Restructuring

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced an operational

  11. Ocular Therapeutix™ To Report Third Quarter 2019 Financial Results

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it

  12. Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it

  13. Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the

  14. Ocular Therapeutix™ to Present at the 2019 Cantor Global Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

  15. Ocular Therapeutix™ to Present at the 2019 Wells Fargo Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that